Alberto Farolfi
Overview
Explore the profile of Alberto Farolfi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farolfi A, Montanari D, Casadei C, Musolino A
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002940
For years, treatment options for advanced gynecological malignancies have been limited, with the combination of carboplatin and paclitaxel being the preferred first-line therapeutic approach, regardless of disease type [...].
2.
Tuninetti V, Farolfi A, Rognone C, Montanari D, De Giorgi U, Valabrega G
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519001
The management of advanced endometrial cancer (EC) has changed in the last few years due to the introduction of a new molecular classification and the approval of immunotherapy. For a...
3.
Pagan E, Ruggeri M, Bianco N, Bucci E, Graffeo R, Borner M, et al.
Breast
. 2024 Jul;
77:103765.
PMID: 39002281
Purpose: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET...
4.
Pasto B, Buzzatti G, Schettino C, Malapelle U, Bergamini A, De Angelis C, et al.
Crit Rev Oncol Hematol
. 2024 May;
199:104379.
PMID: 38718940
The emerging era of precision medicine is characterized by an increasing availability of targeted anticancer therapies and by the parallel development of techniques to obtain more refined molecular data, whose...
5.
Farolfi A, Gentili N, Testoni S, Rusconi F, Massa I, Danesi V, et al.
iScience
. 2024 Apr;
27(5):109680.
PMID: 38646168
Endometriosis is a benign condition characterized by the presence of ectopic endometrial tissue. Our study investigated the effect of endometriosis on the risk of endometrial cancer (EC) and the prognosis...
6.
Passarelli A, Carbone V, Pignata S, Mazzeo R, Lorusso D, Scambia G, et al.
Gynecol Oncol
. 2024 Mar;
183:61-67.
PMID: 38518529
Objective: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a...
7.
Casadei C, Scarpi E, Conteduca V, Gurioli G, Cursano M, Brighi N, et al.
Eur Urol Open Sci
. 2024 Feb;
61:44-51.
PMID: 38384439
Background: The prevalence of pathogenic germline mutations in DNA damage repair (gDDR) genes in the Italian population is unknown. Objective: In this prospective multicenter cohort study, we evaluated the prevalence...
8.
Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, et al.
Front Oncol
. 2023 Sep;
13:1221096.
PMID: 37664032
Introduction: Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC)...
9.
El Zarif T, Nassar A, Pond G, Zhuang T, Master V, Nazha B, et al.
J Natl Cancer Inst
. 2023 Aug;
115(12):1605-1615.
PMID: 37563779
Background: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors....
10.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, et al.
Lancet Oncol
. 2023 Apr;
24(3):286-296.
PMID: 37052965
Background: Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel...